HIGH
POINT, N.C., March 29,
2022 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq:
VTVT) today reported financial results for the fourth quarter and
year ended December 31, 2021, and
provided an update on the progress of its clinical programs.
"I am dedicated to the long-term growth and development of the
Company and look forward to working with vTv's talented employees,
scientists, and partners during this exciting time," Mr.
Nelson said. "The positive Phase 2 study results and FDA
Breakthrough Therapy Designation for TTP339 are very
promising milestones in the development of a novel treatment for
type 1 diabetes patients worldwide"
Recent Achievements and Outlook
Corporate
- Leadership. On March 1,
2022, the Company appointed Richard
Nelson as Acting Chief Executive Officer. Mr. Nelson joined
the vTv Board of Directors in 2020, and currently serves as
Executive Vice President Corporate & Business Development of
Vericast Corp., and Executive Vice President Corporate Development
for MacAndrews & Forbes Incorporated. He brings more than 25
years of business and legal experience in mergers &
acquisitions and corporate development.
Mr. Nelson will work closely with the Company's Board of Directors
as vTv continues to progress in the development of its pipeline of
novel therapeutics, particularly TTP339, an orally
administered treatment for type 1 diabetes.
- Strategic Focus. We plan to prioritize the development
of our lead program TTP399, a novel, oral liver selective
glucokinase activator, as a potential treatment for patients with
type 1 diabetes ("T1D"), as well as continuing to support our
currently partnered programs. Given the strategic focus on these
programs, we plan to pause our development activities in
the United States on HPP737
while we evaluate strategic options for it. As part of this planned
strategic focus, the Company has reduced its workforce. We are
actively seeking to raise non-dilutive capital through licensing
TTP399 in regions outside of North
America and Europe and are
also actively seeking licensing deals for HPP737 and other
assets. We are currently in active discussions with respect to
financing, partnering, and licensing transactions for the further
development of TTP399.
Type 1 Diabetes
- Mechanistic Study of Ketoacidosis with TTP399. In
October 2021, we announced positive
results from the Mechanistic study indicating no increased risk of
ketoacidosis with TTP399 during acute insulin withdrawal in
patients with T1D. Patients with type 1 diabetes taking
TTP399 experienced no increase in ketone levels relative to
placebo during a period of acute insulin withdrawal, indicating
that treatment with TTP399 presents no increased risk of
ketoacidosis. In addition, patients taking TTP399 had
improved fasting plasma glucose levels and experienced fewer
hypoglycemic events relative to those taking placebo, consistent
and supportive of the previously announced phase 2 Simplici-T1
Study results. Full study results will be published in the Diabetes
Obesity and Metabolism journal in conjunction with the
82nd American Diabetes Association Scientific Sessions
on June 6th, 2022.
- Pivotal Study Planning. The Company is planning two
pivotal, placebo-controlled clinical trials of TTP399 in
subjects with type 1 diabetes and has engaged with the Food and
Drug Administration (FDA) on the optimal clinical trial designs for
these studies. The studies will recruit a total of approximately
1000 patients and at least one of the studies will be one year of
treatment. The FDA and the company have agreed on the primary
endpoint for the studies as the difference between placebo and
TTP399-treated group in number of hypoglycemia events. These
pivotal studies are expected to start in 3Q 2022.
Fourth Quarter 2021 Financial Results
- Cash Position: The Company's cash position as of
December 31, 2021, was $13.4 million compared to $19.6 million as of September 30, 2021.
- Revenue: Revenue for the fourth quarter of 2021 was an
insignificant amount. Revenue for the third quarter of 2021 was
$3.0 million, attributable to the
satisfaction of milestones under the license agreements with
Newsoara Biopharma Co., Ltd. (with respect to HPP737) and
Reneo Pharmaceuticals, Inc (with respect to HPP593).
- R&D Expenses: Research and development expenses were
$5.4 million and $2.4 million in each of the three months ended
December 31, 2021, and September 30, 2021, respectively. The changes are
attributable to i) increases due to manufacturing and analytical
work related to chemistry manufacturing and control "CMC" for
pivotal studies, and the startup of TTP399 toxicology
studies in Q4 2021, offset by lower costs in the quarter as the
majority of the TTP399-118 trial was completed earlier in
the year, ii) $2.0 million for a
license payment to Novo Nordisk for the completion of TTP399
phase 2 studies, iii) an increased severance accrual of
$0.6 million, offset by iv)
reductions in bonus and share based compensation due to the
reduction in workforce in Q4 2021 of $0.3
million.
- G&A Expenses: General and administrative expenses
were $5.7 million and $2.2 million for each of the three months ended
December 31, 2021, and September 30, 2021. The changes are attributable
to i) increases in severance expense of $1.5
million in connection with the Company's restructuring plan
that occurred in December 2021, ii)
$0.5 million in stock-based
compensation expense due to the modification of awards related to
the retirement and separation agreements with several key
employees, and iii) increases in legal expense of $1.2 million.
- Other Income/(Expense): Other income for the three
months ended December 31, 2021, was
$1.6 million and was driven by
changes in the fair value of our investment in Reneo as well as the
gains related to a reduction in the fair value of the outstanding
warrants to purchase shares of our own stock issued to a related
party ("Related Party Warrants"). Other income for the three months
ended September 30, 2021, was
$0.2 million and was attributable to
the gains related to a reduction in fair value of the Related Party
Warrants offset by losses driven by the decrease in the fair value
of our investment in Reneo.
- Net Loss Before Non-Controlling Interest: Net loss
before non-controlling interest was $9.5
million for the fourth quarter of 2021 compared to net loss
before non-controlling interest of $1.5
million for the third quarter of 2021. The increase in net
loss before Non-Controlling Interest was primarily attributable to
i) increased severance expense of $2.1
million, ii) $2.0 million for
a license payment to Novo for the completion of TTP399 phase
2 studies, iii) an increase in legal expense of $1.2 million and iv) $0.5
million in stock-based compensation expense due to the
modification of awards related to the retirement and separation
agreements with several key employees.
- Net Loss Per Share: Diluted net loss per share was
($0.11) for the three months ended
December 31, 2021, compared to
diluted net loss per share of ($0.02)
for the three months ended September 30,
2021, based on weighted average diluted shares of 66.8
million and 61.1 million for the three-month periods ended
December 31, 2021, and September 30, 2021, respectively.
Full Year 2021 Financial Results
- Revenue: Revenues were $4.0
million and $6.4 million for
the years ended December 31, 2021,
and 2020, respectively. The 2021 revenue is attributable to the
reallocation of revenue to the license and technology transfer
performance obligation made in connection with an amendment to the
license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co.
with respect to TTP273 as well as increases to the
transaction prices for the license performance obligations under
the Newsoara and Reneo License Agreements due to the satisfaction
of development milestones. The 2020 revenue is attributable to the
upfront payment and fair value of the equity interest received by
the Company in connection with the license agreement with Anteris
Bio (with respect to HPP971).
- R&D Expenses: Research and development expenses were
$13.3 million and $11.0 million for the years ended December 31, 2021, and 2020, respectively. This
increase was attributable to i) spending of $2.3 million for the development of HPP737
as we were conducting a Phase 1 multiple ascending dose study for
this drug candidate, ii) $2.0 million
for a license payment to Novo for the completion of TTP399
phase 2 studies, iii) spending of $1.7
million related to the development of TTP399 due to
the mechanistic study and compound manufacturing, and iv) costs of
$1.6 million for various employee
related costs including severance costs related to the Company's
restructuring plan, increase in share-based compensation, and
reversal of certain performance-based compensation accruals in the
prior year due to the expectation they would not be paid. These
increases were offset by a decrease in clinical trial costs of
$5.3 million for azeliragon
which was mainly driven by discontinuance of its development as a
potential treatment of Alzheimer's disease in patients with type 2
diabetes.
- G&A Expenses: General and administrative expenses
were $12.3 million and $7.3 million for the years ended December 31, 2021, and 2020, respectively. Such
increases were primarily driven by i) severance expense of
$1.5 million in connection with the
Company's restructuring plan that occurred in December 2021, ii) $0.5
million in stock-based compensation expense due to the
modification of awards related to the retirement and separation
agreements with several key employees and general increase in
expense from options issued late 2020, iii) a reversal of certain
performance-based compensation accruals in the prior year due to
the expectation they would not be paid, and iv) $1.2 million of additional legal expenses.
- Other Income/(Expense): Other income/(expense) was
$4.1 million and $(0.3) million for the years ended December 31, 2021, and 2020, respectively. The
increase was driven by an unrealized gain recognized related to the
Company's investment in Reneo as well as the gains related to a
reduction in fair value of the Related Party Warrants.
- Net Loss Before Non-Controlling Interest: Net loss
before non-controlling interest was $17.6
million and $12.8 million for
the years ended December 31, 2021,
and 2020, respectively. The increase in net loss before
Non-Controlling Interest was attributable to i) increased severance
expense of $2.1 million, ii)
$2.0 million for a license payment to
Novo for the completion of TTP399 phase 2 studies, iii)
increases in legal expense of $1.2
million and iv) $0.5 million
in stock-based compensation expense due to the modification of
awards related to the retirement and separation agreements with
several key employees.
- Net Loss Per Share: GAAP net loss per share was
$0.21 and $0.18 for the years ended December 31, 2021, and 2020, respectively, based
on weighted average outstanding shares of 60.7 million and 47.1
million for the years ended December 31,
2021, and 2020, respectively. Non-GAAP adjusted net loss per
fully exchanged share was $0.14 and
$0.17 for the years ended
December 31, 2021, and 2020,
respectively, based on non-GAAP fully exchanged weighted average
shares outstanding of 83.8 million and 70.2 million for the years
ended December 31, 2021, and 2020,
respectively.
vTv Therapeutics Inc.
Condensed
Consolidated Balance Sheets
(in
thousands)
|
|
|
|
|
December 31,
|
|
|
September 30,
|
|
|
2021
|
|
|
2021
|
|
|
|
|
|
|
(Unaudited)
|
|
Assets
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
$
|
13,415
|
|
|
$
|
19,566
|
|
Accounts receivable, net
|
|
57
|
|
|
|
928
|
|
Prepaid expenses and other current assets
|
|
2,049
|
|
|
|
1,574
|
|
Current deposits
|
|
100
|
|
|
|
103
|
|
Total current
assets
|
|
15,621
|
|
|
|
22,171
|
|
Property and equipment,
net
|
|
278
|
|
|
|
300
|
|
Operating lease
right-of-use assets
|
|
402
|
|
|
|
424
|
|
Long-term
investments
|
|
9,173
|
|
|
|
8,539
|
|
Total assets
|
$
|
25,474
|
|
|
$
|
31,434
|
|
Liabilities, Redeemable Noncontrolling Interest and
Stockholders' Deficit
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses
|
$
|
8,023
|
|
|
$
|
4,663
|
|
Operating lease liabilities
|
|
184
|
|
|
|
176
|
|
Current portion of contract liabilities
|
|
35
|
|
|
|
35
|
|
Current portion of notes payable
|
|
256
|
|
|
|
636
|
|
Total current
liabilities
|
|
8,498
|
|
|
|
5,510
|
|
Contract liabilities,
net of current portion
|
|
—
|
|
|
|
9
|
|
Operating lease
liabilities, net of current portion
|
|
492
|
|
|
|
540
|
|
Warrant liability,
related party
|
|
1,262
|
|
|
|
2,260
|
|
Other
liabilities
|
|
-
|
|
|
|
50
|
|
Total
liabilities
|
|
10,252
|
|
|
|
8,369
|
|
Commitments and
contingencies
|
|
|
|
|
|
|
|
Redeemable
noncontrolling interest
|
|
24,962
|
|
|
|
44,610
|
|
Stockholders'
deficit:
|
|
|
|
|
|
|
|
Class A Common Stock
|
|
669
|
|
|
|
665
|
|
Class B Common Stock
|
|
232
|
|
|
|
232
|
|
Additional paid-in capital
|
|
238,193
|
|
|
|
236,557
|
|
Accumulated deficit
|
|
(248,834)
|
|
|
|
(258,999)
|
|
Total stockholders'
deficit attributable to vTv Therapeutics Inc.
|
|
(9,740)
|
|
|
|
(21,545)
|
|
Total liabilities,
redeemable noncontrolling interest and stockholders'
deficit
|
$
|
25,474
|
|
|
$
|
31,434
|
|
vTv Therapeutics Inc.
Condensed
Consolidated Statements of Operations - Unaudited
(in thousands,
except per share data)
|
|
|
|
|
Three Months Ended
|
|
|
December 31, 2021
|
|
|
September 30, 2021
|
|
Revenue
|
$
|
9
|
|
|
$
|
3,000
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
Research and development
|
|
5,402
|
|
|
|
2,382
|
|
General and administrative
|
|
5,716
|
|
|
|
2,221
|
|
Total operating
expenses
|
|
11,118
|
|
|
|
4,603
|
|
Operating
income/(loss)
|
|
(11,109)
|
|
|
|
(1,603)
|
|
Interest
expense
|
|
(6)
|
|
|
|
(6)
|
|
Other income (expense),
net
|
|
1,632
|
|
|
|
244
|
|
Loss before income
taxes and noncontrolling interest
|
|
(9,483)
|
|
|
|
(1,365)
|
|
Income tax
provision
|
|
—
|
|
|
|
100
|
|
Net loss before
noncontrolling interest
|
|
(9,483)
|
|
|
|
(1,465)
|
|
Less: net
income/(loss) attributable to noncontrolling interest
|
|
(2,432)
|
|
|
|
(378)
|
|
Net income/(loss)
attributable to vTv Therapeutics Inc.
|
$
|
(7,051)
|
|
|
$
|
(1,087)
|
|
Net income/(loss)
attributable to vTv Therapeutics Inc. common
shareholders
|
$
|
(7,051)
|
|
|
$
|
(1,087)
|
|
Net
loss per share of vTv Therapeutics Inc. Class A
Common Stock, basic and diluted
|
$
|
(0.11)
|
|
|
$
|
(0.02)
|
|
Weighted average number of vTv Therapeutics Inc.
Class A Common Stock, basic and
diluted
|
|
66,785,550
|
|
|
|
61,073,280
|
|
vTv Therapeutics Inc.
Condensed
Consolidated Statements of Operations
(in thousands,
except per share data)
|
|
|
|
|
Three Months Ended
December 31,
|
|
|
For the Year Ended
December 31,
|
|
|
2021
|
|
|
2020
|
|
|
2021
|
|
|
2020
|
|
|
(Unaudited)
|
|
|
|
|
Revenue
|
$
|
9
|
|
|
$
|
6,399
|
|
|
$
|
4,005
|
|
|
$
|
6,414
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
5,402
|
|
|
|
2,534
|
|
|
|
13,324
|
|
|
|
11,015
|
|
General and administrative
|
|
5,716
|
|
|
|
2,035
|
|
|
|
12,343
|
|
|
|
7,251
|
|
Total operating
expenses
|
|
11,118
|
|
|
|
4,569
|
|
|
|
25,667
|
|
|
|
18,266
|
|
Operating
loss
|
|
(11,109)
|
|
|
|
1,830
|
|
|
|
(21,662)
|
|
|
|
(11,852)
|
|
Interest
income
|
|
—
|
|
|
|
—
|
|
|
|
1
|
|
|
|
12
|
|
Interest
expense
|
|
(6)
|
|
|
|
(67)
|
|
|
|
(12)
|
|
|
|
(692)
|
|
Other income (expense),
net
|
|
1,632
|
|
|
|
(156)
|
|
|
|
4,057
|
|
|
|
(270)
|
|
Loss before income
taxes and noncontrolling interest
|
|
(9,483)
|
|
|
|
1,607
|
|
|
|
(17,616)
|
|
|
|
(12,802)
|
|
Income tax
provision
|
|
—
|
|
|
|
—
|
|
|
|
115
|
|
|
|
—
|
|
Net loss before
noncontrolling interest
|
|
(9,483)
|
|
|
|
1,607
|
|
|
|
(17,731)
|
|
|
|
(12,802)
|
|
Less: net loss
attributable to noncontrolling interest
|
|
(2,432)
|
|
|
|
481
|
|
|
|
(4,744)
|
|
|
|
(4,303)
|
|
Net loss attributable
to vTv Therapeutics Inc.
|
$
|
(7,051)
|
|
|
$
|
1,126
|
|
|
$
|
(12,987)
|
|
|
$
|
(8,499)
|
|
Net loss attributable
to vTv Therapeutics Inc. common shareholders
|
$
|
(7,051)
|
|
|
$
|
1,126
|
|
|
$
|
(12,987)
|
|
|
$
|
(8,765)
|
|
Net
loss per share of vTv Therapeutics Inc. Class A Common
Stock, basic and diluted
|
$
|
(0.11)
|
|
|
$
|
0.02
|
|
|
$
|
(0.21)
|
|
|
$
|
(0.18)
|
|
Weighted average number of vTv Therapeutics Inc. Class
A
Common Stock, basic and
diluted
|
|
66,785,550
|
|
|
|
74,397,085
|
|
|
|
60,732,636
|
|
|
|
47,137,917
|
|
About vTv Therapeutics
vTv Therapeutics Inc. is a
clinical stage biopharmaceutical company focused on developing
oral, small molecule drug candidates. vTv has a pipeline of
clinical drug candidates led by programs for the treatment of type
1 diabetes. vTv's development partners are pursuing additional
indications in type 2 diabetes, chronic obstructive pulmonary
disease, renal disease, primary mitochondrial myopathy, and
pancreatic cancer.
Forward-Looking Statements
This release contains
forward-looking statements, which involve risks and uncertainties.
These forward-looking statements can be identified by the use of
forward-looking terminology, including the terms "anticipate,"
"believe," "could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "will,"
"would" and, in each case, their negative or other various or
comparable terminology. All statements other than statements of
historical facts contained in this release, including statements
regarding the timing of our clinical trials, our strategy, future
operations, future financial position, future revenue, projected
costs, prospects, plans, objectives of management and expected
market growth are forward-looking statements. These statements
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance, or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Important factors that could cause our
results to vary from expectations include those described under the
heading "Risk Factors" in our Annual Report on Form 10-K and our
other filings with the SEC. These forward-looking statements
reflect our views with respect to future events as of the date of
this release and are based on assumptions and subject to risks and
uncertainties. In addition, we may not be able to successfully
complete a successful financing, partnering or licensing
transactions with respect to TTP399. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements. These forward-looking statements
represent our estimates and assumptions only as of the date of this
release and, except as required by law, we undertake no obligation
to update or review publicly any forward-looking statements,
whether as a result of new information, future events or otherwise
after the date of this release. We anticipate that subsequent
events and developments will cause our views to change. Our
forward-looking statements do not reflect the potential impact of
any future acquisitions, merger, dispositions, joint ventures, or
investments we may undertake. We qualify all of our forward-looking
statements by these cautionary statements.
Non-GAAP Financial Measures
To supplement our
consolidated financial statements, which are prepared and presented
in accordance with generally accepted accounting principles in the
U.S. ("GAAP"), we use non-GAAP adjusted net income/(loss) per fully
exchanged share, which is a non-GAAP financial measure. Non-GAAP
adjusted net loss per fully exchanged share adjusts the net loss
attributable to vTv common shareholders for the impact of
adjustments related to outstanding warrants, share-based
compensation expense and the portion of net loss attributable to
the noncontrolling interest. It also assumes the exchange of all
the Class B common stock of vTv Therapeutics Inc. and an equal
number of non-voting common units of vTv Therapeutics LLC ("vTv
Units") for shares of Class A common stock of vTv Therapeutics Inc.
We believe that this measure provides useful information to
investors as it eliminates the variability of non-controlling
interest resulting from the exchanges of Class B common stock and
vTv Units into Class A common stock and other items of a non-cash
nature. This measure is not intended to be considered in isolation
or as a substitute for, or superior to, financial measures prepared
and presented in accordance with GAAP.
The following is a reconciliation of non-GAAP adjusted net loss
per fully exchanged share, basic and diluted to its most directly
comparable GAAP measure, net loss per share of vTv Therapeutics
Inc. Class A common stock, basic and diluted and the computation of
the components of this non-GAAP measure:
|
Three Months Ended
|
|
|
December 31,
2021
|
|
|
September 30,
2021
|
|
Numerator:
|
|
|
|
|
|
|
|
Net
income/(loss) attributable to vTv Therapeutics Inc. common
shareholders
|
$
|
(7,051)
|
|
|
$
|
(1,087)
|
|
Other income/(expense) - related party
|
|
998
|
|
|
|
(1,328)
|
|
Share-based compensation expense
|
|
994
|
|
|
|
474
|
|
Unrealized gain on investments
|
|
634
|
|
|
|
(1,814)
|
|
Reallocation of net income attributable to
noncontrolling
interest from the assumed exchange of Class B shares
(1)
|
|
(2,432)
|
|
|
|
(378)
|
|
Adjusted net income/(loss)
before noncontrolling interest
|
$
|
(6,857)
|
|
|
$
|
(4,133)
|
|
Denominator:
|
|
|
|
|
|
|
|
Weighted average number of vTv Therapeutics Inc.
Class A Common Stock, diluted
|
|
66,785,550
|
|
|
|
61,073,280
|
|
Assumed exchange of Class B Common Stock
(1)
|
|
23,093,860
|
|
|
|
23,093,860
|
|
Adjusted proforma fully
exchanged weighted average
shares of
Class A common stock outstanding, diluted
|
|
89,879,410
|
|
|
|
84,167,140
|
|
Adjusted net loss per
fully exchanged share, diluted
|
$
|
(0.08)
|
|
|
$
|
(0.05)
|
|
|
Three Months Ended
December 31,
|
|
|
Twelve Months Ended
December 31,
|
|
|
2021
|
|
|
2020
|
|
|
2021
|
|
|
2020
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
income/(loss) attributable to vTv Therapeutics Inc. common
shareholders
|
$
|
(7,051)
|
|
|
$
|
1,126
|
|
|
$
|
(12,987)
|
|
|
$
|
(8,499)
|
|
Other income/(expense) - related party
|
|
998
|
|
|
|
(156)
|
|
|
|
1,609
|
|
|
|
(270)
|
|
Share-based compensation expense
|
|
994
|
|
|
|
272
|
|
|
|
2,356
|
|
|
|
1,009
|
|
Unrealized gain on investments
|
|
634
|
|
|
|
—
|
|
|
|
2,448
|
|
|
|
—
|
|
Reallocation of net income attributable to
noncontrolling
interest from the assumed exchange of Class B shares
(1)
|
|
(2,432)
|
|
|
|
481
|
|
|
|
(4,744)
|
|
|
|
(4,303)
|
|
Adjusted net income/(loss)
before noncontrolling interest
|
$
|
(6,857)
|
|
|
$
|
1,723
|
|
|
$
|
(11,318)
|
|
|
$
|
(12,063)
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of vTv Therapeutics Inc.
Class A Common Stock, diluted
|
|
66,785,550
|
|
|
|
74,397,085
|
|
|
|
60,732,636
|
|
|
|
47,137,917
|
|
Assumed exchange of Class B Common Stock
(1)
|
|
23,093,860
|
|
|
|
—
|
|
|
|
23,093,860
|
|
|
|
23,094,221
|
|
Adjusted proforma fully
exchanged weighted average
shares of
Class A common stock outstanding,
diluted
|
|
89,879,410
|
|
|
|
74,397,085
|
|
|
|
83,826,496
|
|
|
|
70,232,138
|
|
Adjusted net
income/(loss) per fully exchanged share,
diluted
|
$
|
(0.08)
|
|
|
$
|
0.02
|
|
|
$
|
(0.14)
|
|
|
$
|
(0.17)
|
|
|
|
(1)
|
Assumes the exchange of
all outstanding Class B common stock, resulting in the inclusion of
shares of Class B common stock in the weighted average share count,
if not already considered, and the elimination of the
noncontrolling interest and recognition of the net income
attributable to noncontrolling interests.
|
Contacts
Investors:
IR@vtvtherapeutics.com.
or
Media:
PR@vtvtherapeutics.com
View original
content:https://www.prnewswire.com/news-releases/vtv-therapeutics-announces-2021-fourth-quarter-and-full-year-financial-results-and-provides-corporate-update-301513417.html
SOURCE vTv Therapeutics Inc.